Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer

Gynecologic Oncology

Volumn 116, Issue 3, 2010, Pages 364-369

  Shih, K K ^a   Chi, D S ^a   Barakat, R R ^a   Leitao Jr , M M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Epithelial ovarian cancer; Fallopian tube cancer; Primary peritoneal cancer; Quarternary cytoreduction; Tertiary cytoreduction

Indexed keywords

ANTIBIOTIC AGENT; PLATINUM DERIVATIVE;

ABDOMINAL ABSCESS; ADJUVANT THERAPY; ADULT; ARTICLE; BILE DUCT OBSTRUCTION; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CELLULITIS; CLINICAL ARTICLE; COLON FISTULA; CYSTOCOLIC FISTULA; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; ILEUS; JAUNDICE; MEDICAL RECORD REVIEW; MINIMAL RESIDUAL DISEASE; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; SURVIVAL RATE; UTERINE TUBE CARCINOMA; VAGINA BLEEDING; WOUND INFECTION;

ADULT; AGED; EPITHELIAL CELLS; FALLOPIAN TUBE NEOPLASMS; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 75749104598     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.10.047     Document Type: Article

References (28)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J. Clin. 58 (2008) 71-96
2. Eisenkop S.M., Friedman R.L., and Wang H.J. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol. Oncol. 69 (1998) 103-108
3. Muggia F.M., Braly P.S., Brady M.F., et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J. Clin. Oncol. 18 (2000) 106-115
4. Griffiths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl. Cancer Inst. Monogr. 42 (1975) 101-104
5. Hacker N.F., Berek J.S., Lagasse L.D., Nieberg R.K., and Elashoff R.M. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet. Gynecol. 61 (1983) 413-420
6. Piver M.S., Lele S.B., Marchetti D.L., Baker T.R., Tsukada Y., and Emrich L.J. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J. Clin. Oncol. 6 (1988) 983-989
7. Hoskins W.J., Bundy B.N., Thigpen J.T., and Omura G.A. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol. Oncol. 47 (1992) 159-166
8. Hoskins W.J., McGuire W.P., Brady M.F., et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol. 170 (1994) 974-979 discussion 9-80
9. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., and Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20 (2002) 1248-1259
10. Fader A.N., and Rose P.G. Role of surgery in ovarian carcinoma. J. Clin. Oncol. 25 (2007) 2873-2883
11. Chi D.S., Eisenhauer E.L., Lang J., et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?. Gynecol. Oncol. 103 (2006) 559-564
12. Morris M., Gershenson D.M., and Wharton J.T. Secondary cytoreductive surgery in epithelial ovarian cancer: nonresponders to first-line therapy. Gynecol. Oncol. 33 (1989) 1-5
13. Morris M., Gershenson D.M., Wharton J.T., Copeland L.J., Edwards C.L., and Stringer C.A. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol. Oncol. 34 (1989) 334-338
14. Segna R.A., Dottino P.R., Mandeli J.P., Konsker K., and Cohen C.J. Secondary cytoreduction for ovarian cancer following cisplatin therapy. J. Clin. Oncol. 11 (1993) 434-439
15. Eisenkop S.M., Friedman R.L., and Wang H.J. Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study. Cancer 76 (1995) 1606-1614
16. Vaccarello L., Rubin S.C., Vlamis V., et al. Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. Gynecol. Oncol. 57 (1995) 61-65
17. Eisenkop S.M., Friedman R.L., and Spirtos N.M. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 88 (2000) 144-153
18. Gadducci A., Iacconi P., Cosio S., Fanucchi A., Cristofani R., and Riccardo Genazzani A. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol. Oncol. 79 (2000) 344-349
19. Zang R.Y., Zhang Z.Y., Li Z.T., et al. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer. Eur. J. Surg. Oncol. 26 (2000) 798-804
20. Tay E.H., Grant P.T., Gebski V., and Hacker N.F. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet. Gynecol. 99 (2002) 1008-1013
21. Gungor M., Ortac F., Arvas M., Kosebay D., Sonmezer M., and Kose K. The role of secondary cytoreductive surgery for recurrent ovarian cancer. Gynecol. Oncol. 97 (2005) 74-79
22. Chi D.S., McCaughty K., Diaz J.P., et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106 (2006) 1933-1939
23. Salani R., Santillan A., Zahurak M.L., et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer 109 (2007) 685-691
24. Oksefjell H., Sandstad B., and Trope C. The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer. Ann. Oncol. (2008)
25. Leitao Jr. M.M., Kardos S., Barakat R.R., and Chi D.S. Tertiary cytoreduction in patients with recurrent ovarian carcinoma. Gynecol. Oncol. 95 (2004) 181-188
26. Karam A.K., Santillan A., Bristow R.E., et al. Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome. Gynecol. Oncol. 104 (2007) 377-380
27. Benedet J.L., Bender H., Jones III H., Ngan H.Y., and Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int. J. Gynaecol. Obstet. 70 (2000) 209-262
28. Berek J.S., Hacker N.F., Lagasse L.D., Nieberg R.K., and Elashoff R.M. Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet. Gynecol. 61 (1983) 189-193